KGK Science has been issued a Cannabis Research Licence by Health Canada under the Cannabis Regulations allowing KGK to possess and administer cannabis for purposes of a clinical trial. According to the company, this licence is one of the first of its kind to be issued to a contract research organization in Canada.
"In its first cannabis-based clinical trial, KGK will be testing the pharmacokinetics of THC and CBD in healthy adults," the team with the company explains. "Based on a protocol developed by KGK researchers, the trial will commence in October 2019 at KGK’s in-house clinic in London, Ontario, with results being later delivered to the third-party sponsor who has privately contracted KGK to conduct this trial on their behalf."
“This is a much-needed step forward for our business, our clients, and for the cannabis industry as a whole,” said Najla Guthrie, President and CEO of KGK. “Support from government and regulatory bodies is essential for cannabis product manufacturers to take a responsible, science-driven approach to substantiating the safety and efficacy of their products through clinical trials.”
"For nearly two decades, KGK has served many of North America’s nutraceutical, natural health product and consumer packaged goods companies. KGK works with its clients in offering well-designed, customized solutions and substantiating claims for their products through randomized clinical trials."
For more information:
KGK Science
kgkscience.com